novonordisk
Novo Nordisk, the Danish drug maker of the wildly successful obesity drugs, Wegovy and Ozempic, said it plans to invest $4.1 billion for a new plant in the United States to increase the manufacturing capacity of its high demand drugs. The new plant will be in Clayton, North Carolina, where the company plans to produce current and future injectable treatments for people with obesity and other serious chronic diseases. These mainly include weight loss drug Wegovy and diabetes treatment Ozempic, among others. As per reports, demand for Wegovy and Ozempic have grown significantly over supply in th...
DPA International
Novo Nordisk, the Danish drug maker of the wildly successful obesity drugs, Wegovy and Ozempic, said it plans to invest $4.1 billion for a new plant in the United States to increase the manufacturing capacity of its high demand drugs. The new plant will be in Clayton, North Carolina, where the company plans to produce current and future injectable treatments for people with obesity and other serious chronic diseases. These mainly include weight loss drug Wegovy and diabetes treatment Ozempic, among others. As per reports, demand for Wegovy and Ozempic have grown significantly over supply in th...
DPA
Novo Nordisk, the Danish drug maker of the wildly successful obesity drugs, Wegovy and Ozempic, said it plans to invest $4.1 billion for a new plant in the United States to increase the manufacturing capacity of its high demand drugs. The new plant will be in Clayton, North Carolina, where the company plans to produce current and future injectable treatments for people with obesity and other serious chronic diseases. These mainly include weight loss drug Wegovy and diabetes treatment Ozempic, among others. As per reports, demand for Wegovy and Ozempic have grown significantly over supply in th...
DPA Breaking News
The second fire the company has faced in less than a week. The fire had started outside but later spread to an office building at the company's Bagsvaerd location, which houses the global headquarters of Novo, maker of the blockbuster Wegovy weight-loss treatment and the Ozempic diabetes drug.
Euronews (English)
For more than a year, there has been a rising trend in using diabetes drugs such as Ozempic solely for its weight loss effect. As with any medication, there are potential risks of side effects that you may or may not have been aware of initially. For instance, in 2023, American Jaclyn Bjorklund launched legal proceedings against Novo Nordisk and Eli Lilly and Co, the manufacturers of Ozempic and Mounjaro respectively, alleging severe gastrointestinal complications, particularly gastroparesis characterised by a paralysis of the stomach. Ozempic: How a TikTok weight loss trend caused a global di...
Euronews (English)
The weight-loss drug semaglutide - commonly sold under the brand names Ozempic and Wegovy - reduced cardiovascular events such as stroke and heart attack in adults with preexisting disease independent of weight loss. It also helped people keep their weight down for at least four years. That is according to two new analyses of a large trial presented at the European Congress on Obesity in Venice on Monday. Semaglutide is the main active ingredient in the popular weight-loss jabs Ozempic and Wegovy. It mimics the GLP-1 hormone which can signal that your body is full. The analyses looked at the S...
Euronews (English)
In plans aimed at revolutionising healthcare and other life sciences, Novo Holdings is investing DKK 1.4 billion (€188 million) in building a hub of start-ups focused on new technologies including quantum computing. Quantum computers, capable of making scientific calculations that would otherwise take most computers thousands of years, can potentially speed up the development of pharmaceuticals and other life sciences. Novo Holdings is the parent company of Europe's most valuable firm, Novo Nordisk, known for its weight-loss medication Wegovy and Ozempic, a diabetes drug. "Quantum technologies...
Euronews (English)
Profit increased in the first quarter for Danish pharmaceutical company Novo Nordisk compared to the previous year. First-quarter net profit increased by 28% to 25.41 billion Danish kroner ($3 billion), the company reported. Earnings per share increased by 29% to 5.68 kroner. Operating profit increased by 27% in kroner and by 30% at constant exchange rates (CER) to 31.8 billion kroner. First quarter sales increased by 22% measured in kroner and by 24% at CER to 65.35 billion kroner in the first three months of 2024. For 2024, the company now expects operating profit growth to be 22% to 30% at ...
DPA International
Profit increased in the first quarter for Danish pharmaceutical company Novo Nordisk compared to the previous year. First-quarter net profit increased by 28% to 25.41 billion Danish kroner ($3 billion), the company reported. Earnings per share increased by 29% to 5.68 kroner. Operating profit increased by 27% in kroner and by 30% at constant exchange rates (CER) to 31.8 billion kroner. First quarter sales increased by 22% measured in kroner and by 24% at CER to 65.35 billion kroner in the first three months of 2024. For 2024, the company now expects operating profit growth to be 22% to 30% at ...
DPA
Profit increased in the first quarter for Danish pharmaceutical company Novo Nordisk compared to the previous year. First-quarter net profit increased by 28% to 25.41 billion Danish kroner ($3 billion), the company reported. Earnings per share increased by 29% to 5.68 kroner. Operating profit increased by 27% in kroner and by 30% at constant exchange rates (CER) to 31.8 billion kroner. First quarter sales increased by 22% measured in kroner and by 24% at CER to 65.35 billion kroner in the first three months of 2024. For 2024, the company now expects operating profit growth to be 22% to 30% at ...
DPA Breaking News
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら